The possibility of mutations of RAS signaling genes and/or TP53 in combination as a negative prognostic impact on pathological stage I non-small cell lung cancer.
Takayuki HondaKatsutoshi SetoSatoshi EndoAkira TakemotoKousuke TanimotoMasashi KobayashiMasatake KitanoRie SakakibaraTakahiro MitsumuraHironori IshibashiJohji InazawaToshihiro TanakaYasunari MiyazakiKenichi OkuboPublished in: Cancer medicine (2023)
Mutations in RAS signaling genes and/or TP53 could be useful for the prediction of shorter RFS of patients with stage I NSCLC.